DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Renal Cell Carcinoma – Unmet Need – Unmet Need – Advanced or Metastatic Renal Cell Carcinoma (US/EU)
The treatment of advanced or metastatic renal cell carcinoma is dominated by immune checkpoint inhibitors (e.g., Merck & Co.’s Keytruda, BMS’s Opdivo and Yervoy) and small-molecule tyrosine…
Pulmonary Arterial Hypertension | Treatment Algorithms: Claims Data Analysis | US | 2024
Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder characterized by high blood pressure in the arteries of the lungs. It is a progressive condition marked by considerable…
Gastroesophageal Cancer – Unmet Need – Unmet Need – Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (US/EU)
Approximately 40% of gastric and gastroesophageal junction (GEJ) adenocarcinoma patients present with metastasis, and half of patients with localized disease progress to metastatic disease…
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Progression Independent of Relapse Activity (US/EU)
Marketed DMTs for multiple sclerosis deliver a high level of efficacy in preventing relapses and relapse-associated worsening of disability (RAW). However, MS patients still experience disability…
Pancreatic Cancer – Unmet Need – Unmet Need – Locally Advanced or Metastatic Pancreatic Adenocarcinoma (US/EU)
Pancreatic adenocarcinoma is an aggressive malignancy associated with an extremely poor prognosis and high lethality. The metastatic setting is the largest drug-treatable population in pancreatic…
